ASLN (ASLN) Stock Analysis
DELISTED 2024
What happened to ASLN (ASLN) stock?
ASLN (ASLN) no longer trades on public markets. It was delisted in July 2024. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- July 2024
- Last recorded price (historical):
- $0.60 (last quote on record before the July 2024 delisting; historical, not a current quote)
Market cap $777M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
ASLN (ASLN). ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology treatments. Its primary focus is on developing ASLAN004 for atopic dermatitis and other immunological conditions, alongside ASLAN003 for autoimmune diseases.
Last analyzed: Jun 14, 2026Dated analysis: the newest financial statements on file are 31 months old (Mar 1, 2024), so the figures and score below describe that period, not today.
ASLN (ASLN) Healthcare & Pipeline Overview
ASLN ADR Information Sponsored
ASLN (ASLN) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy ASLN shares?
No. ASLN stopped trading on public markets in July 2024, so the shares are not available through a broker. Anything you see quoted for ASLN elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ASLN stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ASLN. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.